Bank of New York Mellon’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-3,900
Closed -$119K 4280
2015
Q4
$119K Sell
3,900
-6,745
-63% -$212K ﹤0.01% 4015
2015
Q3
$317K Buy
10,645
+10,201
+2,298% +$327K ﹤0.01% 3750
2015
Q2
$14K Buy
444
+155
+54% +$5.05K ﹤0.01% 4244
2015
Q1
$10K Hold
289
﹤0.01% 4216
2014
Q4
$9K Buy
+289
New +$8.29K ﹤0.01% 4233
2014
Q2
Sell
-394
Closed -$12K 4235
2014
Q1
$12K Hold
394
﹤0.01% 4160
2013
Q4
$11K Buy
+394
New +$11.5K ﹤0.01% 4187

Other funds holding PFE

Bank of New York Mellon's PFE Position: Q2 2026 in Review

Bank of New York Mellon increased its Pfizer (PFE) stake by 7.4% in Q2 2026, buying an estimated $105M and bringing the position to 57,879,546 shares worth $1.39B. The position accounts for 0.23% of the portfolio, ranked #70.

Bank of New York Mellon first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.18B in Q1 2015. 2,239 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Bank of New York Mellon held 57,879,546 shares of Pfizer worth $1.39B as of Q2 2026.
  • Bank of New York Mellon bought 3,999,646 Pfizer shares in Q2 2026, an estimated $105M.
  • Pfizer made up 0.23% of Bank of New York Mellon's portfolio in Q2 2026, its #70 holding.
  • Bank of New York Mellon first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Bank of New York Mellon's Pfizer position peaked at $4.18B in Q1 2015.
  • 2,239 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.